IDYA vs. RXRX

Last updated Apr 1, 2026

Compare and contrast key facts about IDEAYA Biosciences, Inc. (IDYA) and Recursion Pharmaceuticals, Inc. (RXRX).

Performance

IDYA vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in IDEAYA Biosciences, Inc. (IDYA) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

IDYA vs. RXRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
IDYA IDEAYA Biosciences, Inc.	-3.62%	34.51%	-27.77%	95.82%	-23.14%	27.03%
RXRX Recursion Pharmaceuticals, Inc.	-25.18%	-39.50%	-31.44%	27.89%	-54.99%	-45.27%

Fundamentals

Market Cap IDYA : $2.95B RXRX : $1.61B
EPS IDYA : -$1.28 RXRX : -$1.39
PS Ratio IDYA : 13.55 RXRX : 19.03
PB Ratio IDYA : 2.89 RXRX : 1.43
Total Revenue (TTM) IDYA : $218.71M RXRX : $74.56M
Gross Profit (TTM) IDYA : $214.12M RXRX : $3.73M
EBITDA (TTM) IDYA : -$120.40M RXRX : -$579.69M

Returns By Period

In the year-to-date period, IDYA achieves a -3.62% return, which is significantly higher than RXRX's -25.18% return.

IDYA

• 1D: 5.95%
• 1M: 3.48%
• YTD: -3.62%
• 6M: 22.45%
• 1Y: 103.42%
• 3Y*: 34.38%
• 5Y*: 6.93%
• 10Y*: —

RXRX

• 1D: -0.33%
• 1M: -15.70%
• YTD: -25.18%
• 6M: -40.00%
• 1Y: -39.94%
• 3Y*: -22.87%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

IDYA vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDYA

IDYA Risk / Return Rank: 89
IDYA Sharpe Ratio Rank: 90
IDYA Sortino Ratio Rank: 86
IDYA Omega Ratio Rank: 84
IDYA Calmar Ratio Rank: 93
IDYA Martin Ratio Rank: 92

RXRX

RXRX Risk / Return Rank: 18
RXRX Sharpe Ratio Rank: 19
RXRX Sortino Ratio Rank: 22
RXRX Omega Ratio Rank: 23
RXRX Calmar Ratio Rank: 15
RXRX Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IDYA vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for IDEAYA Biosciences, Inc. (IDYA) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IDYA	RXRX	Difference
Sharpe ratio Return per unit of total volatility	1.98	-0.48	+2.46
Sortino ratio Return per unit of downside risk	2.48	-0.32	+2.80
Omega ratio Gain probability vs. loss probability	1.32	0.97	+0.35
Calmar ratio Return relative to maximum drawdown	4.76	-0.72	+5.48
Martin ratio Return relative to average drawdown	12.04	-1.43	+13.47
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

IDYA vs. RXRX - Sharpe Ratio Comparison

The current IDYA Sharpe Ratio is 1.98, which is higher than the RXRX Sharpe Ratio of -0.48. The chart below compares the historical Sharpe Ratios of IDYA and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	IDYA	RXRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.98	-0.48	+2.46
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.12	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.23	-0.40	+0.63

Correlation

The correlation between IDYA and RXRX is 0.42, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

IDYA vs. RXRX - Dividend Comparison

Neither IDYA nor RXRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

IDYA vs. RXRX - Drawdown Comparison

The maximum IDYA drawdown since its inception was -74.64%, smaller than the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for IDYA and RXRX.

Drawdown Indicators

	IDYA	RXRX	Difference
Max Drawdown Largest peak-to-trough decline	-74.64%	-93.13%	+18.49%
Max Drawdown (1Y) Largest decline over 1 year	-20.05%	-58.17%	+38.12%
Max Drawdown (5Y) Largest decline over 5 years	-69.42%	—	—
Current Drawdown Current decline from peak	-29.30%	-92.60%	+63.30%
Average Drawdown Average peak-to-trough decline	-30.82%	-74.78%	+43.96%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.92%	29.48%	-21.56%

Volatility

IDYA vs. RXRX - Volatility Comparison

IDEAYA Biosciences, Inc. (IDYA) has a higher volatility of 15.78% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 14.66%. This indicates that IDYA's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	IDYA	RXRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.78%	14.66%	+1.12%
Volatility (6M) Calculated over the trailing 6-month period	31.74%	54.53%	-22.79%
Volatility (1Y) Calculated over the trailing 1-year period	52.65%	83.97%	-31.32%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	59.78%	94.52%	-34.74%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.51%	94.52%	-20.01%

Financials